Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma
- PDF / 507,852 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 9 Downloads / 216 Views
ORIGINAL ARTICLE
Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma Shuichi Mitsunaga 1,2
&
Eiji Kasamatsu 3 & Koji Machii 3
Received: 28 November 2019 / Accepted: 2 February 2020 # The Author(s) 2020
Abstract Purpose Cachexia influences the patient’s physical wellbeing and quality of life, and the patient’s ability to tolerate their cancer therapies, especially cytotoxic chemotherapy. The purpose of this study was to investigate the frequency and timing of onset of cancer cachexia during chemotherapy and its association with prognosis and toxicity in patients with pancreatic ductal adenocarcinoma (PDAC). Methods We performed a retrospective study in patients who underwent first-line chemotherapy after diagnosis of advanced PDAC between 6 June 2008 and 31 March 2017. Base cachexia (weight loss up to 6 months before starting first-line chemotherapy) and follow-up cachexia (after starting first-line chemotherapy) were defined as weight loss > 2% with a body mass index (BMI) < 20 kg/m2 or weight loss > 5%. Results A total of 150 patients were registered. The median age and BMI were 65 years and 21.7 kg/m2, respectively. Base cachexia occurred in 50% of patients. Follow-up cachexia occurred in 32% within 12 weeks of starting first-line chemotherapy, reaching 64% at 1 year. Overall survival was not significantly different between patients with and without follow-up cachexia, regardless of whether cancer cachexia occurred within 12, 24, or 48 weeks of starting first-line treatment. Appetite loss, fatigue, nausea, and diarrhea were more frequent in patients with follow-up cachexia than in those without follow-up cachexia. Conclusion Follow-up cachexia had an early onset, but was not a prognostic factor for overall survival in patients with PDAC. Some adverse events tended to be more frequent in patients with follow-up cachexia than in those without follow-up cachexia. Keywords Cachexia . Incidence . Survival . Pancreatic cancer . Adverse events
Introduction Cancer cachexia is a multi-factorial metabolic syndrome characterized by ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00520-020-05346-8) contains supplementary material, which is available to authorized users. * Shuichi Mitsunaga [email protected] 1
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
2
Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan
3
Medical Affairs Department, Ono Pharmaceutical Co., Ltd, Osaka, Japan
to progressive functional impairment. Its pathophysiology is characterized by a hypercatabolic state driven by reduced food intake and abnormal metabolism [1]. It is now becoming clear that cancer cachexia has an impact on the pati
Data Loading...
